3H-benzo[d][1,2]oxazine-1,4-dione | 31583-39-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 3H-benzo[d][1,2]oxazine-1,4-dione
• 英文别名: 1H-2,3-benzoxazine-1,4-dione；benzo[d][1,2]oxazine-1,4-dione；2,3-benzoxazine-1,4(3H)-dione；2,3-Benzoxazine-1,4-quinone；2,3-benzoxazine-1,4-dione
• CAS: 31583-39-8
• 化学式: C₈H₅NO₃
• 分子量: 163.133
• InChiKey: XJLZMLDQBCAVLW-UHFFFAOYSA-N

物化性质

• 熔点：
  222-225 °C
• 密度：
  1.402±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3H-benzo[d][1,2]oxazine-1,4-dione 在 N-甲基羟胺 、 potassium chloride 作用下， 以 乙腈 为溶剂， 生成 2-(羟基氨基甲酰基)苯甲酸
  参考文献：
  名称：

  Khan, Mohammad Niyaz, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1996, vol. 35, # 12, p. 1275 - 1281

  摘要：

  DOI：
• 作为产物：
  描述：

  3-(1-methylethenyl)-1H-2,3-benzoxazine-1,4(3H)-dione 反应 1.0h， 以98%的产率得到3H-benzo[d][1,2]oxazine-1,4-dione
  参考文献：
  名称：

  Synthesis of 3,5-Isoxazolidinediones and 1H-2,3-Benzoxazine-1,4(3H)-diones from Aliphatic Oximes and Dicarboxylic Acid Chlorides

  摘要：

  The synthesis of the title compounds was carried out by reacting dicarboxylic acid chlorides with oximes in the presence of excess triethylamine. Disubstituted malonyl chlorides gave 2-alkenyl-4,4-dialkyl-3,5-isoxazolidinediones (8a-f) and 2,2;-ethylidene-bis[4,4-dialkyl-3,5-isoxazolidinedione]s (9a-f). Compounds 9 were formed from 8 and its N-unsubstituted 3,5-isoxazolidinedione decomposition product. Phthaloyl chlorides reacted with acetone oxime to yield 3-(1-methylethenyl)-1H-2,3-benzoxazine-1,4(3H)-diones (16a-e). Products 16 spontaneously decomposed to give N-unsubstituted 1H-2,3-benzoxazine-1,4(3H)-diones (17a-e) at rates that were dependent on temperature and solvent. Kinetic studies showed that two of the compounds decomposed by zero-order kinetics under neutral conditions. Butanedioyl chloride did not produce a cyclic product.

  DOI：

  10.1021/jo402708j

文献信息

• Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds
  申请人：Konradi W. Andrei

  公开号：US20070021555A1

  公开（公告）日：2007-01-25

  Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions.

  揭示了一种使用Mitsunobu条件制备农业、治疗和食品添加剂化合物的聚合物共轭物的过程。
• NANOPARTICLES FOR DRUG DELIVERY
  申请人：Nantz Michael H.

  公开号：US20120302516A1

  公开（公告）日：2012-11-29

  The invention provides magnetic nanoparticles comprising a core, wherein the nanoparticles comprise at least one therapeutic agent linked to the core via a hydrazone linkage or via an oxime ether linkage, methods for making said nanoparticles, and methods for using said nanoparticles.

  该发明提供了磁性纳米颗粒，包括一个核心，其中纳米颗粒通过肼酰肼键或肟醚键与至少一种治疗剂连接，制备该纳米颗粒的方法以及使用该纳米颗粒的方法。
• Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds
  申请人：Konradi Andrei W.

  公开号：US20130018187A1

  公开（公告）日：2013-01-17

  Disclosed is a process for preparing polymer conjugates of agricultural, therapeutic, and food additive compounds using Mitsunobu conditions.

  揭示了一种使用Mitsunobu条件制备农业、治疗和食品添加剂化合物的高分子共轭物的过程。
• Azocompounds for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
  申请人：UNIVERSITY OF PITTSBURGH

  公开号：EP1110945A2

  公开（公告）日：2001-06-27

  Amyloid binding compounds which are derivatives of Chrysamine G, pharmaceutical compositions containing, and methods using such compounds to identify Alzheimer's brain in vivo and to diagnose other pathological conditions characterized by amyloidosis, such as Down's Syndrome are described. Pharmaceutical compositions containing Chrysamine G and derivatives thereof and methods using such compositions to prevent cell degeneration and amyloid-induced toxicity in amyloidosis associated conditions are also described. Methods using Chrysamine G derivatives to stain or detect amyloid deposits in biopsy or post-mortem tissue are also described. Methods using Chrysamine G derivatives to quantify amyloid deposits in homogenates of biopsy and post-mortem tissue are also described.

  本文描述了作为金黄胺 G 衍生物的淀粉样蛋白结合化合物、含有此类化合物的药物组合物以及使用此类化合物鉴定体内阿尔茨海默氏症大脑和诊断以淀粉样变性为特征的其他病理状况（如唐氏综合症）的方法。此外，还描述了含有金黄胺 G 及其衍生物的药物组合物，以及使用此类组合物在淀粉样变性相关病症中防止细胞变性和淀粉样诱导毒性的方法。还介绍了使用金黄胺 G 衍生物染色或检测活检或死后组织中淀粉样沉积物的方法。还介绍了使用金黄胺 G 衍生物量化活检组织和死后组织匀浆中淀粉样蛋白沉积的方法。
• Kinetics of Action of a Two-Stage Pro-Inhibitor of Serine β-Lactamases
  作者：Ronak Tilvawala、R. F. Pratt

  DOI：10.1021/bi400873r

  日期：2013.10.8

  beta-Lactamase inhibitors are important in medicine in the protection of beta-lactam antibiotics from beta-lactamase-catalyzed destruction. The most effective inhibitors of serine beta-lactamases covalently modify the enzyme active site. We have recently studied O-acyl and O-phosphyl hydroxamates as a new class of such inhibitors. In this paper, we describe our studies of the N-acyl derivatives of a cyclic O-acyl hydroxamic acid, 3H-benzo[d][1,2]oxazine-1,4-dione, and, in particular, the N-tert-butoxycarbonyl derivative. This compound is not a beta-lactamase inhibitor itself but undergoes spontaneous hydrolysis in aqueous solution, yielding an O-phthaloyl hydroxamic acid, which is a beta-lactamase inhibitor. This compound spontaneously, but reversibly, cyclizes in solution to form phthalic anhydride, which is also a beta-lactamase inhibitor. Both inhibitors react to form the same transiently stable phthaloyl-enzyme complex. Thus, we have a two-step cascade, beginning with a pro-inhibitor, in which each step leads to a different inhibitor, presumably with different enzyme specificities. The kinetics of these transformations have been elucidated in detail. The phthaloyl derivatives, where the free carboxylate is important for facile reaction with the enzyme, represent a new lead for serine beta-lactamase inhibitors. Analogues can be conveniently constructed in situ by reaction of nucleophiles with phthalic anhydrides and then screened for activity. Active hits may then become new leads.